| Welcome to The Morning Filter, your guide to the busy news day ahead. We hope you are staying safe. Here are the latest updates and the big news stories to follow today: 1. U.K. approval of Oxford-AstraZeneca COVID-19 vaccine Serum Institute of India on Wednesdsay termed the approval for Oxford-AstraZeneca COVID-19 vaccine in the U.K. as encouraging news and said that the company would now wait for the final nod for the medication in India. 2. CDSCO expert panel to reconvene on Jan 1 to consider emergency use authorisation for COVID vaccines An expert panel in the Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday to consider emergency use authorisation applications by the SII for the Oxford COVID-19 vaccine and Bharat Biotech's 'Covaxin' will reconvene on January 1 to further deliberate on the matter. 3. Govt likely to take call on SC collegium recommendations to transfer HC CJs by Thursday Sources said most of the paper work has been completed and a decision could be known by December 31. 4. New Year's Eve | No entry for vehicles without passes to Connaught Place, parking limited in Delhi  People busy with New Year shopping at a market in the Capital. Delhi Police on Wednesday issued a traffic advisory for New Year's Eve which will be applicable to all private and public transport vehicles and will come into effect from Thursday 8 p.m. in the city. 5. New Year's Eve | Liquor shops in Telangana allowed to be open till 12 a.m.Liquor shops will remain open till midnight on Thursday in Telangana in view of new year eve celebrations, the State Prohibition and Excise Department said. 6. Coronavirus | Latest numbers and developments The number of positive coronavirus cases reported from India now stands at 1,02,65,778 at the time of publishing this newsletter. The death toll from the disease stands at 1,48,794. Morning Filter will return tomorrow. Follow up on the day's biggest stories and get concise analysis by The Hindu with the Evening Wrap newsletter. Click here to get it in your inbox. | 
Post a Comment